Hipertansif Hastalarda Aldosteron Fazlalığının Hematolojik Parametreler ve İnflamatuvar İndekslerle İlişkisi

İLKER CORDAN , Ferda SEVİMLİ , Çiğdem Damla Deniz , Oğuzhan Aksu

  • İLKER CORDAN: Sağlık Bilimleri Üniversitesi Konya Şehir Hastanesi
  • Ferda SEVİMLİ: SAĞLIK BİLİMLERİ ÜNİVERSİTESİ KONYA ŞEHİR HASTANESİ
  • Çiğdem Damla Deniz: Sağlık bilimleri üniversitesi-Konya Şehir Hastanesi
  • Oğuzhan Aksu: Sağlık bilimleri üniversitesi-Konya Şehir Hastanesi
  • Year : 2026
  • Vol : 42
  • Issue : 1
  •  Page : 41-49
Amaç: Primer aldosteronizm (PA), sekonder hipertansiyonun en yaygın nedenlerinden biri olmasına rağmen sıklıkla tanı konulamamaktadır. Bu çalışmada, PA
taramasında kullanılan biyokimyasal belirteçler olan plazma aldosteron konsantrasyonu (PAC), plazma renin aktivitesi (PRA) ve aldosteron-renin oranı (ARR) ile
hemogram analizinden elde edilen lökosit, nötrofil, lenfosit ve trombosit (PLT) sayıları ve bu parametrelerden türetilen nötrofil/lenfosit oranı (NLR), trombosit/lenfosit
oranı (PLR) ve Sistemik İmmün-İnflamasyon İndeksi (SII) gibi göstergeler arasındaki ilişkilerin değerlendirilmesi amaçlanmıştır.
Gereç ve Yöntemler: Bu retrospektif çalışmada, Ocak 2021–Aralık 2023 tarihleri arasında PA taraması yapılan 169 hipertansif hastanın verileri analiz edildi. Hastalar
PAC eşik değerlerine göre ≥15 ng/dL ve ≥30 ng/dL olmak üzere iki gruba ayrıldı. PAC, PRA ve hematolojik parametreler arasındaki ilişkiler korelasyon analizi, çok
değişkenli lineer regresyon ve ROC eğrisi analizi kullanılarak değerlendirildi.
Bulgular: Trombosit sayısı, hem PAC ≥15 ng/dL hem de PAC ≥30 ng/dL gruplarında anlamlı olarak daha yüksek bulundu (sırasıyla p = 0.041 ve p < 0.001). Çok değişkenli
regresyon analizinde PLT (p = 0.001), PLR (p = 0.012) ve SII (p = 0.044) PAC ile bağımsız olarak ilişkili kaldı. ROC analizinde trombosit sayısının PAC ≥30 ng/dL için
istatistiksel olarak anlamlı bir ROC paterni gösterdiği saptandı (AUC = 0.727; p = 0.001).
Sonuç: Lökosit temelli hematolojik parametreler ve inflamatuvar indeksler PA tarama belirteçleri ile anlamlı ilişki göstermemiştir. Bununla birlikte, trombosit sayısı ile
PAC arasındaki mütevazı ilişki, trombosit sayısının aldosteron aktivitesi ile ilişkili olabileceğini düşündürmektedir. Bu bulgunun klinik öneminin netleşmesi için daha
ileri çalışmalara ihtiyaç vardır.
Cite this Article As : Cordan I, Sevimli F, Deniz CD, Aksu O. Association of Aldosterone Excess with Hematological Parameters and Inflammatory Indices in Hypertensive Patients. Selcuk Med J 2026;42(1): 41-49

Download Citation: Endnote/Zotero/Mendeley (RIS) RIS File

Download Citation: BibTeX BibTeX File

Conflict of interest : The authors declare that they have no conflict of interest.
This article is published under the CC BY-NC 4.0 license.
Selcuk Medical Journal
2026, Vol. 42 (1)
ISSN: 1017-6616
E-ISSN: 2149-8059
Received : , Accepted : , Published Online :

References

  1. 1. Savard S, Amar L, Plouin PF, et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331–336. doi:10.1161/HYPERTENSIONAHA.113.01060
  2. 2. Yozamp N, Vaidya A. The prevalence of primary aldosteronism and evolving approaches for treatment. Curr Opin Endocr Metab Res. 2019;8:30-39. doi:10.1016/j.coemr.2019.07.001.
  3. 3. Funder JW, Carey RM. Primary aldosteronism: where are we now? Where to from here? Hypertension. 2022;79(4):726–735. doi:10.1161/HYPERTENSIONAHA.121.18761
  4. 4. Rossi GP, Rossi FB, Guarnieri C, et al. Clinical management of primary aldosteronism: an update. Hypertension. 2024;81(9):1845-1856. doi:10.1161/HYPERTENSIONAHA.124.22642.
  5. 5. Dogra P, Bancos I, Young WF Jr. Primary aldosteronism: a pragmatic approach to diagnosis and management. Mayo Clin Proc. 2023;98(8):1207-1215. doi:10.1016/j.mayocp.2023.04.023.
  6. 6. Xu JP, Zeng RX, Zhang YZ, et al. Systemic inflammation markers and the prevalence of hypertension: a NHANES cross-sectional study. Hypertens Res. 2023;46(4):1009–1019. doi:10.1038/s41440-023-01195-0
  7. 7. Aljuraiban GS, Gibson R, Oude Griep LM. Associations of systematic inflammatory markers with diet quality, blood pressure, and obesity in the AIRWAVE Health Monitoring Study. J Inflamm Res. 2024;17:3129-3141. doi:10.2147/JIR.S459238
  8. 8. Ferreira NS, Tostes RC, Paradis P, et al. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 2021;34(1):15-27. doi:10.1093/ajh/hpaa137
  9. 9. Szczepanek-Parulska E, Adamska M, Korda O, et al. Changes in complete blood count parameters influenced by endocrine disorders. Endokrynol Pol. 2021;72(3):261-270. doi:10.5603/EP.a2021.0059
  10. 10. Libianto R, Hu J, Chee MR, et al. A multicenter study of neutrophil-to-lymphocyte ratio in primary aldosteronism. J Endocr Soc. 2020;4(12):bvaa153. doi:10.1210/jendso/bvaa153
  11. 11. Kurisu S, Shimonaga T, Iwasaki T, et al. Mean platelet volume in patients with primary aldosteronism and its relation to left ventricular hypertrophy. Int J Cardiol. 2013;168(3):3143-3144. doi:10.1016/j.ijcard.2013.04.156
  12. 12. Adler GK, Stowasser M, Correa RR, et al. Primary aldosteronism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2025;110(9):2453-2495. doi:10.1210/clinem/dgaf284.
  13. 13. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061
  14. 14. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212-6222. doi:10.1158/1078-0432.CCR-14-0442
  15. 15. Li X, Liu M, Wang G. The neutrophil-lymphocyte ratio is associated with all-cause and cardiovascular mortality in cardiovascular patients. Sci Rep. 2024;14(1):26692. doi:10.1038/s41598-024-76836-6.
  16. 16. Rao KR, Bao RY, Ming H, et al. The correlation between aldosterone and leukocyte-related inflammation: a comparison between patients with primary aldosteronism and essential hypertension. J Inflamm Res. 2023;16:2401-2413. doi:10.2147/JIR.S409146.
  17. 17. Guo X, Liu C, Hu S, et al. Neutrophil-to-lymphocyte ratio can predict the clinical prognosis of patients with primary aldosteronism. Eur Heart J. 2024;45(Suppl 1):ehae666.2529. doi:10.1093/eurheartj/ehae666.2529.
  18. 18. Cao Y, Li P, Zhang Y, et al. Association of systemic immune inflammatory index with all-cause and cause-specific mortality in hypertensive individuals: Results from NHANES. Front Immunol. 2023;14:1087345. doi:10.3389/fimmu.2023.1087345.
  19. 19. Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50(5):e13230. doi:10.1111/eci.13230.
  20. 20. Zhu F, Wang Z, Song J, et al. Correlation analysis of inflammatory markers with the short-term prognosis of acute ischaemic stroke. Sci Rep. 2024;14(1):17772. doi:10.1038/s41598-024-66279-4.
  21. 21. Delcea C, Buzea CA, Vîjan AE, et al. The platelet to lymphocyte ratio in heart failure: a comprehensive review. Rom J Intern Med. 2023;61(2):84-97. doi:10.2478/rjim-2023-0006.
  22. 22. Otsuka H, Abe M, Kobayashi H. The effect of aldosterone on cardiorenal and metabolic systems. Int J Mol Sci. 2023;24(6):5370. doi:10.3390/ijms24065370.
  23. 23. Gromotowicz A, Szemraj J, Stankiewicz A, et al. Study of the mechanisms of aldosterone prothrombotic effect in rats. J Renin Angiotensin Aldosterone Syst. 2011;12(4):430-439. doi:10.1177/1470320310397405.
  24. 24. Bodary PF, Sambaziotis C, Wickenheiser KJ, et al. Aldosterone promotes thrombosis formation after arterial injury in mice. Arterioscler Thromb Vasc Biol. 2006;26(1):233. doi:10.1161/01.ATV.0000195782.07637.44.
  25. 25. Gromotowicz-Poplawska A, Marcinczyk N, Misztal T, et al. Rapid effects of aldosterone on platelets, coagulation, and fibrinolysis lead to experimental thrombosis augmentation. Vascul Pharmacol. 2019;122-123:106598. doi:10.1016/j.vph.2019.106598.
  26. 26. Gromotowicz-Poplawska A, Flaumenhaft R, Gholami SK, et al. Enhanced thrombotic responses are associated with striatin deficiency and aldosterone. J Am Heart Assoc. 2021;10(22):e022975. doi:10.1161/JAHA.121.022975.
  27. 27. Sala C, Rescaldani M, Gherbesi E, et al. Platelet cyclic GMP levels are reduced in patients with primary aldosteronism. J Clin Med. 2023;12(22):7081. doi:10.3390/jcm12227081.
  28. 28. Moraes LA, Paul-Clark MJ, Rickman A, et al. Ligand-specific glucocorticoid receptor activation in human platelets. Blood. 2005;106(13):4167-4175. doi:10.1182/blood-2005-04-1723.
  29. 29. Gomi T, Ikeda T, Shibuya Y, et al. Effects of antihypertensive treatment on platelet function in essential hypertension. Hypertens Res. 2000;23(6):567-572. doi:10.1291/hypres.23.567
  30. 30. Levy PJ, Yunis C, Owen J, et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol. 2000 Dec 1;86(11):1188-92. doi: 10.1016/s0002-9149(00)01200-5.
  31. 31. Lv X, Hu H, Shen C, et al. Risk factors associated with lower bone mineral density in primary aldosteronism patients. Front Endocrinol (Lausanne). 2022;13:884302. doi:10.3389/fendo.2022.884302.
  32. 32. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982-1004. doi:10.1097/HJH.0000000000002453.
  33. 33. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480.
  34. 34. Chung I, Lip GY. Platelets and heart failure. Eur Heart J. 2006;27(22):2623-2631. doi:10.1093/eurheartj/ehl305.
figure1
figure1
figure 2
figure 2
figure 3
figure 3
figure 4A
figure 4A
figure 4B
figure 4B
figure1
figure1
figure 2
figure 2
figure 3
figure 3
figure 4A
figure 4A
figure 4B
figure 4B
Figure 4.
Figure 4.